Scientific Online Resource System

Annual for Hospital Pharmacy

Analysis Of The Efficiency Of Historical Treatment Costs Of Patients With Invasive Fungal Infections

Toni Vekov, Jivko Kolev

Abstract

The study presents the modeling of local data on the costs and health benefits of CYP51 inhibitors (CYP51i) for the treatment of invasive fungal infections and the implementation of an indirect comparison based on network meta-analysis. The results of our assessment are confirmed by the results of the same health technology assessments conducted in Spain and the United States. Voriconazole is a cost-effective therapy compared to fluconazole for pharmacotherapy and prevention of invasive fungal infections (ICER 1020 lv / QALY) and dominates itraconazole with improved therapeutic efficacy and lower cost of treatment. Posaconazole is not cost-effective therapy compared to voriconazole because of its too high cost and an unfavorable incremental cost-benefit ratio and additional health benefits (ICER 145 000 lv./QALY).

Keywords

invasive fungal infections, CYP51 inhibitors, cost / effectiveness analysis

Full Text


References

Kradin RL, Mark EJ. The pathology of pulmonary disorders due to Aspergillus spp. Arch Pathol Lab Med. 2008 Apr;132(4):606-14.

Neuburger S, Massenkeil G, Seibold M, et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis. 2008 Jul;10(4):290-3.

López Martínez R, Méndez Tovar LJ. Chromoblastomycosis. Clin Dermatol, 2007,25(2):188-94.

Nguyen C1, Barker BM, Hoover S, et al. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of

coccidioidomycosis. Clin Microbiol Rev. 2013 Jul;26(3):505-25.

Rhodus NL. Treatment of oral candidiasis. Northwest Dent. 2012 Mar-Apr;91(2):32-3.

Becher R, Wirsel SG. Fungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens. Appl Microbiol Biotechnol. 2012

Aug;95(4):825-40.

Grigorov E, Vaseva V, Getov I. Applied pharmacoeconomics – methodology, structuring and conducting of pharmacoeconomical studies, J Int Sci Publications:

Economy&Business. 2013 Apr;7(1):540-551.

Study of Posaconazole in the Treatment of Invasive Fungal Infections. NCT00034632. https://clinicaltrials.gov/

Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections. NCT01075984. https://clinicaltrials.gov/

Posaconazole to Treat Invasive Fungal Infections. NCT00033982л https://clinicaltrials.gov

Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction. NCT00686543 https://clinicaltrials.gov

Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.

Grau S, Cámara R, Jurado M, et al. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versushost disease after allogeneic hematopoietic stem cell transplantation. Eur J Health Econ. 2018 May;19(4):627-636.

O‘Sullivan AK, Pandya A, Papadopoulos G et al. Costeffectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value in Health. 2009 Jul-Aug;12(5):666-73.




DOI: http://dx.doi.org/10.14748/.v4i1.5508

Refbacks

Article Tools
Email this article (Login required)
|